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The Royal Marsden NHS Foundation Trust, London, UKThe incidence of cutaneous melanoma is rising faster than thatof any other malignancy, and in some parts of Europe it is now
the commonest cancer outside of ‘‘the big four’’ common
malignancies: i.e. breast, lung, colorectal and prostate cancers.
There is little doubt that the major factors in the development
of melanoma are skin type, racial origin and sun exposure.
Short sharp bursts of sunlight leading to sunburn are danger-
ous, especially when they occur in children and adolescents.
Ten percent of melanomas are familial in origin, and as
with other cancers, the biology associated with such tumours
has helped us to develop an understanding of the molecular
genetics of sporadic melanoma. A number of mutations have
been described, including those found in CDKN2A, CDK4, RB1,
p14ARF, NRAS and particularly BRAF. BRAF mutations are
found in approximately 50% of patients with cutaneous mel-
anoma, and the development of targeted agents against
mutations in BRAF has been responsible for one of the most
dramatic examples of molecular medicine in oncology.
Adjuvant therapy for patients at high risk of relapse
following treatment for primary melanoma or locoregional
disease remains an area of uncertainty. The use of adjuvant
interferon, at various doses and schedules, has been the sub-
ject of many randomised trials over 25 years. It is of note that
some large trial groups such as those in Europe still feel that
there is enough uncertainty as to the efficacy of interferon
that randomised trials of adjuvant therapy should still be per-
formed with a no-treatment control arm. The one indisput-
able fact about adjuvant interferon is that it is associated
with a relapse-free survival benefit, but some argue that, un-
like treatment in the metastatic setting, the purpose of adju-
vant therapy is to improve overall survival. A number of
meta-analyses of the randomised trials involving interferon
have been published, and it appears that the maximum abso-
lute benefit to overall survival is in the order of 2–3% and
again, some argue that this is below the threshold of useful
clinical utility. Randomised trials of the newer melanoma
therapies are now being brought into the adjuvant arena.
Vemurafenib is a BRAF inhibitor, and the results of the
first randomised trial of vemurafenib against standard of care– namely, dacarbazine (DTIC) – were dramatic in terms of
response rates, progression-free survival and overall survival.
The hazard ratio for overall survival at the time of the first
analysis was unprecedented in solid tumour oncology. The
therapeutic momentum has continued with the development
of MEK inhibitors and their combination with BRAF inhibitors.
Other targeted therapies are being developed for uveal and
acral melanomas, e.g. against c-KIT mutations in the latter.
The most important recent development in immunotherapy
has been the targeting of inhibitors of the immune system, e.g.
CTLA-4, PD-1 and its ligand PD-L1. Ipilimumab targets CTLA-4
and is the first immunotherapy to have shown an overall survival
benefit in melanoma within the context of a randomised trial.
The magnitude of benefit can be very great in some patientswith
prolonged complete remissions; however, it is only a minority of
patients that benefit. Early results targeting PD-1 and PD-L1 are
particularlyexcitingbecausetheyappear tochallengethe dogma
that immunotherapy only impacts a minority of patients. Early
results suggest that the majority of patients show some benefit
without necessarily achieving a complete remission.
The new immunotherapeutic landscape means that our
previous view of follow-up needs to change rapidly. We now
know that there is an important immunotherapy that is
associated with a survival advantage, but that, as with most
immunotherapies, it can take some time before the host
response becomes effective. This time-frame may be 2–
4 months, and therefore it is completely illogical to wait for
a patient to become symptomatic from their metastatic dis-
ease before investigating and treating them.
Patients must have their metastatic disease diagnosed
early, otherwise there is little prospect of a successful out-
come to immunotherapy, and therefore patients at high risk
of relapse need regular imaging, and treatment should be
instituted before high volumes of disease are seen.
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